InvestorsHub Logo

TPX

Followers 0
Posts 40567
Boards Moderated 4
Alias Born 10/24/2013

TPX

Re: TPX post# 42811

Thursday, 07/06/2017 11:41:34 AM

Thursday, July 06, 2017 11:41:34 AM

Post# of 50672
Oxis and MultiCell's MultiCell Immunotherapeutics partnered to develop ADCs using Oxis' OXS-2175 for triple-negative breast cancer (TNBC) and OXS-4235 for multiple myeloma (MM)

http://bciq.biocentury.com/deals/deal_427639